A Meta-Analysis of 5-Hydroxytryptamine Receptor 1B Polymorphisms With Risk of Major Depressive Disorder and Suicidal Behavior

Pingliang Yang 1†, Mengchang Yang 2†, Peng Li 2, Dejun Cao 3, Daoyin Gong 4, Jiahua Lv 5, Linmei Pu 5, Sizhou Huang 6* and Yundan Liang 5*

1 Department of Anesthesiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China, 2 Department of Anesthesiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China, 3 Department of Anesthesia, Chengdu Second People’s Hospital, Chengdu, China, 4 Department of Pathology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, 5 Department of Pathology and Pathophysiology, Chengdu Medical College, Chengdu, China, 6 Development and Regeneration Key Laboratory of Sichuan Province, Department of Anatomy and Histology and Embryology, Chengdu Medical College, Chengdu, China

Purpose: Previous association studies have investigated whether genetic polymorphisms in HTR1B influenced individuals’ susceptibility to major depressive disorder (MDD), anti-depressant response (ADR) and suicidal behavior. However, equivocal evidence was obtained. In this meta-analysis, we aimed to examine the association of HTR1B polymorphisms with risk of MDD, ADR and suicidal behavior.

Materials and Methods: Studies evaluating the association between HTR1B polymorphisms and risk of MDD, ADR and suicidal behavior were searched in Pubmed, Ovid Medline, web of science and China National Knowledge Infrastructure databases. Summary odds ratios (ORs), 95% confidence intervals (CIs) and p-values were calculated using a fixed or random effects model.

Results: Meta-analysis findings revealed a significantly increased risk of MDD with rs6296 GC and GC/CC genotypes (GC vs. GG: OR = 1.26, 95% CI, 1.07–1.48; GC/CC vs. GG: OR = 1.22, 95% CI, 1.04–1.43, respectively). Moreover, rs6298 CT genotype was significantly associated with an increased risk of suicidal behavior (CT vs. CC: OR = 1.48, 95% CI, 1.16–1.88). However, both rs6296 and rs130058 were not significant risk factors for lethal suicidal behavior.

Conclusion: This meta-analysis identified that rs6296 and rs6298 in HTR1B may be significantly related to the risk of MDD and lethality of suicide attempts, respectively. Further studies are required to assess the markers in larger cohorts.

Keywords: HTR1B, polymorphism, major depressive disorder, suicidal behavior, meta-analysis
INTRODUCTION

Major depressive disorder (MDD) is a common mental disorder that affects about 216 million people worldwide in 2015 (1). Although a group of anti-depressant agents were used in clinical practice, nearly 30% of patients cannot respond positively to the primary prescription (2, 3) and half of people who died of suicide were related to MDD or other mood disorders (4). The cause of MDD has been demonstrated to be a combination of environmental, psychological and genetic factors (5–8). However, the exact mechanism of genetic contribution in the emergence of MDD and suicidal behavior remains unclear.

The serotoninergic pathway has been implicated to play a crucial role in the pathophysiology of MDD, antidepressant response (ADR) and suicidal behavior (9–12). Some components of this system, such as serotonin receptor 1A, 1B, 2A, 2B, and 2C, are important regulators of metabolism of 5-hydroxytryptamine (5-HT). Among them, 5-HT1B receptor is considered as a nerve terminal autoreceptor, with the function of inhibiting the release of 5-HT. In the hippocampus, activation of postsynaptic 5-HT1B heteroreceptors implicated excitatory synapses as a locus of plasticity in depression (13). The 5-HT1B receptor knockout mice displayed a variety of behavioral paradigms, including lower levels of anxiety (14).

The 5-HT1B receptor is encoded by HTR1B gene in humans (15). Previously, genetic association studies have investigated whether single nucleotide polymorphisms (SNPs) in HTR1B influenced individuals’ susceptibility to MDD and suicidal behavior, such as rs6296, rs6298 and rs130058 (16–27). These SNPs were functional, with rs6296-C allele reducing the levels of HTR1B mRNA, rs6296G-rs6298C or rs6296 G-rs6298 T haplotype exhibiting higher levels of HTR1B mRNA (19), and rs130058 affecting receptor gene activity (28). However, equivocal evidence was obtained. Kao et al. reported that rs6296 GC genotype was significantly associated with an increased risk of MDD and rs6298 CT genotype was significantly associated with an increased risk of suicide attempts (19). Conversely, Rujescu et al. reported that there was no significant association of rs6296 with MDD risk (26). The discrepancy may be caused by limited power in a single study with small samples. In order to evaluate the combined evidence from publications, we designed and conducted a meta-analysis examining the association of HTR1B polymorphisms with risk of MDD, ADR and suicidal behavior.

MATERIALS AND METHODS

Search Strategy

Followed the PRISMA statement, we screened records by conducting computer-based searches of Pubmed, Ovid Medline (1946–2020), web of science (1900–2020) and China National Knowledge Infrastructure (1915–2020) databases using the following search algorithm: (“5-hydroxytryptamine receptor 1B” or “HTR1B”) and (“SNP*” or “polymorphism*” or “variant*” or “susceptibility”) and (“depression” or “major depressive disorder” or “suicide” or “suicidal behavior”). The literature search without language restrictions was carried out up to May 2020.

Eligibility Criteria

The inclusion criteria for study selection were: (a) association studies reporting HTR1B polymorphisms with the risk of MDD or ADR or suicidal behavior and (b) studies published as full-length articles with original genotyping data for computing pooled odds ratios (ORs) and 95% confidence intervals (CIs). The exclusion criteria were: (a) duplicate publications; (b) lack and inaccessibility of data; and (c) meta-analysis. There is no language restriction for inclusion and exclusion criteria.

Data Extraction

From each included study, the following information was independently extracted by two authors (Pingliang Yang and Mengchang Yang) and checked by a third author (Yundan Liang): name of the first author, year of publication, country, ethnic background of participants, total number and mean age of participants, diagnosis and source of patients, criteria used for matching cases, SNPs studied, genotyping distributions, genotyping method, and quality control for genotyping method. Disagreements were solved by discussion among the three authors.

Statistical Analysis

A meta-analysis was performed to investigate the association between HTR1B polymorphisms and the risk of MDD, ADR and suicidal behavior among different genetic models with available data from at least two independent studies. The distributions of SNP genotypes in controls were retested for conformity to Hardy–Weinberg equilibrium (HWE) using a chi-squared test. The Q-test and I² metric were used to test heterogeneity across studies (29). In the absence of any detectable between-study heterogeneity (I²-value <50% and p ≥ 0.10), a fixed effects model was used to compute summary ORs and 95% CIs (30); otherwise, a random effects model was used (31). Meta-regression analysis was used to examine potential reasons for...
| References       | Country  | Ethnicity | Cases                  | Source of controls                                                                 | Matching criteria | Genotyping method | Quality control | Polymorphisms |
|------------------|----------|-----------|------------------------|------------------------------------------------------------------------------------|-------------------|------------------|----------------|--------------|
| Fehr et al. (16) | Germany  | Caucasian | 108                    | DSM-IV MDD patients were recruited from multicenter trials                         | -                 | PCR-RFLP          | -              | rs6296       |
| Hong et al. (17) | China    | Asian     | 110                    | DSM-IV Suicidal individuals were defined as those with a history of attempted suicide | 215 normal subjects | -                | -              | rs130058     |
| Huang et al. (18)| USA      | Mixed     | 340                    | DSM-III-R 208 MDD patients and 132 patients with a history of at least one suicide attempt | 96 healthy volunteers | Age and sex | PCR-RFLP | rs6296       |
| Kao et al. (19)  | China    | Asian     | 476                    | DSM-IV 285 MDD patients and 191 MDD patients with a history of suicide attempts      | -                 | -                | -              | rs6296 and   |
| Rujescu et al. (26)| Germany | Caucasian | 211                    | DSM-IV 148 unrelated suicide attempters and 63 patients with unipolar depressive disorder | -                 | PCR-RFLP          | -              | rs6296       |
| Shaikh et al. (33)| USA      | Mixed     | 201                    | DSM-III or DSM-IV Adult patients receiving treatment for pertinent mood symptoms during childhood were enrolled | -                 | -                | -              | rs6296       |
## TABLE 1 | Continued

| References       | Country | Ethnicity | Number | Age | Diagnosis and Assessment | Source of cases                                                                 | Source of controls | Matching criteria | Genotyping method | Quality control | Polymorphisms |
|------------------|---------|-----------|--------|-----|---------------------------|---------------------------------------------------------------------------------|--------------------|------------------|------------------|-----------------|---------------|
| Silva et al. (34) | Chile   | Mixed     | 59     | 18–65 | DSM-IV                    | Responders were defined as patients with a reduction of ≥75% in HDRS-17 score after 12 weeks of fluoxetine treatment | -                  | PCR-RFLP         | -                | -               | rs6296         |
| Słopieński et al. (35) | Poland      | Caucasian | 332    | 42–67 | HRSD                      | Postmenopausal women with depressive disorder                                   | 219 postmenopausal women | PCR-RFLP         | -                | rs6296         |
| Stefulj et al. (36) | Croatia   | Caucasian | 363    | 49 ± 19 | -                         | Suicide completers                                                              | 440 individuals without personal or family history of neuropsychiatric disorders | PCR-RFLP         | -                | rs6296         |
| Tsai et al. (37)  | China    | Asian     | 160    | 43.9 ± 16.4 (18–74) | DSM-IV        | MDD patients received a 4-week fluoxetine treatment and response was defined as a minimum reduction of 50% in HAMD score after 8 weeks of treatment. | 160 normal subjects | PCR-RFLP         | -                | rs130058        |
| Videtic et al. (38) | Slovenia | Caucasian | 226    | 49.6 ± 17.3 | -                         | Suicide victims                                                                 | 225 blood donors with no history of neuropsychiatric disorders | PCR-RFLP         | -                | rs6296 and rs130058 |
| Wang et al. (39)  | China    | Asian     | 85     | 36.7 ± 14.1 | HAMD-17                   | Patients were treated with single antidepressant escitalopram and 47.1% of the patients achieved remission. Clinical remission was defined as patients with a HAMD score ≥7 or reduction of ≥75% in HAMD score after 8 weeks of treatment. | -                  | PCR-RFLP and PCR-sequencing | -                | rs6296, rs6298, rs1228814 and rs1778258 |
| Wilkie et al. (40) | UK       | Caucasian | 268    | 43.4 ± 11.3 (18–65) | ICD-10 and DSM-IV | 166 patients with unipolar depression and 102 patients with early onset depression | -                  | PCR-RFLP         | -                | rs6296 and rs130058 |
| Xu et al. (41)    | China    | Asian     | 308    | 18–60  | DSM-IV and HDRS-17        | Responders were defined as patients with a reduction of ≥50% in HDRS-17 score after 12 weeks of treatment. | -                  | Illumina GoldenGate assay | -                | rs6298         |
| Zouk et al. (42)  | Canada   | Caucasian | 338    | 38 ± 11 | -                         | Suicide completers                                                              | 358 controls without a history of suicidal behavior or major psychiatric diagnoses | SNaPshot          | -                | rs6296, rs6298, rs130058, –261T/G and 1180A/G |
between-study heterogeneity. Subgroup analyses were performed to assess the consistency of HTR1B polymorphisms among predefined categories of study characteristics such as ethnicity of participants (Asian, Caucasian and mixed population) and outcome of anti-depressant therapy (responder vs. non-response and remitter vs. non-remitter). Publication bias was estimated visually using Egger’s linear regression asymmetry test (32). Sensitivity analyses were reported after excluding each study at a time. Data analysis was performed using Stata version 11.0 (Stata Corporation, College Station, TX). Statistical power was calculated using Quanto software version 1.2.3 (Nataru Software, Naperville, IL, USA).

RESULTS
Flow Diagram of Selection Studies
The flow diagram of selection process is presented in Figure 1. From a total of 185 records retrieved from the primary screening, 92 records were reviewed by title and abstract after removing duplicates (n = 93). Thirty records were excluded based on no MDD (n = 17), no HTR1B polymorphisms (n = 4), no human study (n = 1) and review articles (n = 8). The full-text of the remaining 62 articles was assessed and 41 records were excluded based on no MDD (n = 10), no HTR1B polymorphisms (n = 6), review articles (n = 5), no available data (n = 18) and duplicate data reporting by the same group (n = 2). Finally, 21 studies evaluating the effect of three polymorphisms in HTR1B (i.e., rs6296, rs62983 and rs130058) on MDD, ADR and suicidal behavior were included in this meta-analysis.

Characteristics of Included Studies
The characteristics of the included studies are summarized in Table 1. Of the 21 studies included in this meta-analysis, 6 was conducted in Asians, 11 in Caucasians and 4 in mixed populations reporting more than one ethnic descent. The samples in different studies varied, ranging from 59 to 803. All studies reported genotyping techniques, including polymerase chain reaction (PCR)-restriction fragment length polymorphism, amplification-refractory mutation system, allele-specific PCR, pyrosequencing, Illumina GoldenGate assay and SNAPSHOT.

However, only four studies (19.0%) described matching criteria between cases and controls, and only one study (4.8%) described quality control for genotyping assays.

Eight studies investigated the association between HTR1B rs6296 polymorphism and MDD risk, involving 1,230 cases and 1,863 controls, with a statistical power of 93.5% when setting the relative ratio as 1.3 under a dominant model. The rs6296 genotype distributions in controls of all studies varied, ranging from 59 to 803. All populations reporting more than one ethnic descent. The studies conducted in Asians, 11 in Caucasians and 4 in mixed population) did not reveal any significant association between rs6296 and MDD risk. Following anti-depressant treatment, the difference of the rs6296 genotype frequencies was observed neither in remitters and non-remitters nor in responders and non-responders (Table 2).

For HTR1B polymorphisms with the risk of suicidal behavior, meta-analysis findings revealed that rs6298 CT genotype was significantly associated with an increased risk of suicidal behavior (CT vs. CC: OR = 1.48, 95% CI, 1.16–1.88). However, both rs6296 and rs130058 were not significant risk factors for lethal suicidal.

### Table 2: Meta-analysis of HTR1B rs6296 polymorphism and the risk of MDD and ADR.

| Ethnicity       | Dominant model | Recessive model | Allele comparison |
|-----------------|----------------|-----------------|-------------------|
| Total           | 8              | 1.26 (1.07–1.48) | 0.18              | 0.87 (0.66–1.14) | 0.19              | 1.09 (0.97–1.23) | 0.38              |
| Caucasian       | 5              | 1.09 (0.87–1.36) | 0.67              | 0.96 (0.63–1.45) | 0.10              | 1.06 (0.86–1.31) | 0.40              | 0.92 (0.62–1.38) | 0.16              | 1.03 (0.87–1.21) | 0.17              |
| Mixed           | 2              | 1.23 (0.89–1.69) | 0.70              | 1.38 (0.70–2.75) | 0.47              | 1.25 (0.92–1.70) | 0.87              | 1.27 (0.65–2.49) | 0.41              | 1.19 (0.93–1.53) | 0.85              |
| Remitter vs. non-remitter | 2              | 0.71 (0.47–1.07) | 0.37              | 1.59 (0.74–3.40) | 0.89              | 0.81 (0.55–1.19) | 0.44              | 1.75 (0.84–3.63) | 0.64              | 0.97 (0.71–1.32) | 0.59              |
| Total           | 2              | 0.73 (0.47–1.12) | 0.91              | 0.94 (0.46–1.95) | 0.91              | 0.77 (0.51–1.15) | 0.96              | 1.13 (0.59–2.15) | 0.91              | 0.88 (0.65–1.20) | 0.73              |

MDD, major depressive disorder; ADR, antidepressant response; OR, odd ratio; CI, confidence interval.

---

Yang et al. HTR1B Polymorphisms With MDD/Suicide Risk

Frontiers in Psychiatry | www.frontiersin.org 5 July 2021 | Volume 12 | Article 696655
TABLE 3 | Meta-analysis of HTR1B polymorphisms and the risk of suicide behavior.

| Polymorphisms | n  | Heterozygous comparison | Homozygous comparison | Dominant model | Recessive model |
|---------------|----|-------------------------|-----------------------|----------------|----------------|
|               |    | OR (95% CI)             | P-value               | OR (95% CI)    | P-value        |
| rs6296        | 11 | 1.26 (1.03–1.53)        | 0.02                  | 1.21 (1.00–1.47) | 0.04           |
| Ethnicity     |    |                         |                       |                |                |
| Caucasian     | 7  | 1.29 (1.00–1.65)        | 0.05                  | 1.23 (1.02–1.48) | 0.02           |
| Asian         | 2  | 1.27 (0.89–1.80)        | 0.23                  | 1.21 (0.84–1.75) | 0.29           |
| Mixed         | 2  | 1.09 (0.70–1.71)        | 0.56                  | 1.07 (0.66–1.75) | 0.80           |
| rs130058      | 3  | 1.28 (1.00–1.63)        | 0.06                  | 1.22 (0.97–1.54) | 0.10           |
| Caucasian     | 2  | 1.27 (0.89–1.80)        | 0.23                  | 1.21 (0.84–1.75) | 0.29           |
| Total         | 2  | 1.48 (1.16–1.88)        | 0.01                  | 1.42 (1.05–1.92) | 0.02           |

MDD, major depressive disorder; OR, odds ratio; CI, confidence interval. Numbers of studies, Q-test of heterogeneity; Pooled ORs were computed using the Random-effects model.

Egger's linear regression asymmetry test was used to estimate the publication bias. For publications investigating the association between rs6296 and MDD risk, the funnel plot showed a significance in a dominant genetic model (p = 0.02). The bias disappeared after excluding the study with sample size <200 (16) and the overall effect of rs6296 on MDD risk remains unchanged (OR = 1.28, 95% CI: 1.09–1.51). For publications investigating the association between rs6296 and the risk of suicidal behavior, the funnel plot also showed a significance in homozygous comparison (p = 0.001). The bias disappeared when excluding the studies with sample size <200 (20, 21, 24) and the overall effect of rs6296 on the risk of suicidal behavior remains unaltered (OR = 0.94, 95% CI: 0.73–1.21) (Figure 3).

DISCUSSION

5-HT1B receptor is a nerve terminal autoreceptor that is involved in the modulation of 5-HT synthesis and release in rat brain cortex (43). Mice absence of 5-HT1B receptor were observed to exhibit altered psychiatric disorders, such as increased aggression, alcohol and cocaine intake, as well as lower levels of anxiety (14, 44–46). Growing evidence has shown that 5-HT1B receptor is implicated in the pathophysiology of MDD, serving as a promising new target for antidepressant treatment (47, 48). HTR1B, encoding 5-HT1B receptor, is located on 6q14.1 in human genome. Three common genetic polymorphisms in HTR1B (i.e., rs6296, rs6298, and rs130058) have been widely examined in affective disorders. However, results from previous individual studies are contradictory regarding the role of HTR1B polymorphisms in MDD and suicidal behavior. A meta-analysis is therefore valuable with the objective of offering a comprehensive assessment of the effect of HTR1B polymorphisms on the etiology of MDD and suicidal behavior. Our meta-analysis showed that carriers with rs6296 GC and GC/CC genotypes had a 1.26- and 1.22-fold increased risk of MDD, respectively, and carriers with rs6298 CT genotype had a 1.48-fold increased risk of suicidal behavior. Our study has more than 80% power statistics, indicating the results were solid.
These findings suggested that both rs6296 and rs6298 in HTR1B were significant genetic risk factors for the development and progression of MDD, which was consistent with the data from genome-wide association study (49).

As for rs6296 in HTR1B, no previous meta-analysis of the genetic variant in the onset of MDD has been published to date. This meta-analysis including 8 studies (1,230 cases and 1,863 controls) showed a significantly increased risk of MDD (16, 18, 19, 23, 25, 26, 33, 35), supporting previous results reported by Kao et al. who found that age and rs6296 GC genotype were significantly associated with MDD (19). A possible mechanism of rs6296 enhancing MDD risk is that patients with the rs6296-C allele had lower levels of HTR1B mRNA, displayed more hostility and aggressive behavior, and finally caused a higher risk of MDD and suicidal ideation (19). According to data from 1,000 Genomes, the distribution of rs6296 C allele varied largely among different ethnicities, with a frequency of 50.9% in East Asian, 26.3% in European and 24.4% in African. The distribution variance of rs6296 in different ethnic groups may influence the risk of MDD. We therefore performed subgroup analysis based on ethnicity (Asian, Caucasian and mixed population). However, we did not identify positive effect of rs6296 on MDD risk among Asian, Caucasian and mixed population. These results should be interpreted cautiously because only two studies were performed in mixed population (18, 33) and only one study was performed in Asian (19). To make the results robust, further evidence for a relationship between rs6296 and MDD in diverse ethnic groups is required.

Currently, antidepressants are the first line of treatment for MDD. Conflicting results were obtained regarding the effectiveness of antidepressants (50). Previous work has attempted to find out whether rs6296 in HTR1B was a biological
predictor of antidepressant response (34, 39, 40). The statistical power in each study was insufficient due to small sample sizes, which may lead to type II error and false negative findings. For example, only 49 patients including 22 responders and 27 non-responders were genotyped in Amerindians and Caucasians (34). In this meta-analysis, we reevaluated the effect of rs6296 on the response of antidepressant medication by pooling all the published data together, and we failed to find any significant association of the rs6296 with antidepressant treatment. Even though we added up all the available samples, the total number is still very small and the power may not be strong enough yet for statistical significance. Future studies are necessary to validate the role of HTR1B polymorphisms in pharmacological response to antidepressants.

Globally, MDD is the major reason for suicide, with about 50% of people dying of suicide having MDD or other mood disorders (4, 51). And thus it is of value to examine whether the MDD-risk factor rs6296 is linked to suicidal behavior. After records screening and eligibility process, 11 articles were included in this meta-analysis, involving 1,844 cases and 2,479 controls. Our meta-analysis revealed that rs6296 was not a significant risk factor for lethal suicidal behavior in overall analysis as well as subgroup analysis in terms of ethnicity. These findings were in accordance to a previous meta-analysis conducted in 2007 (52). We cannot rule out the possibility of selection bias of participants that caused the negative results. For instance, the controls in Murphy’s study deviated from HWE (20).

Besides rs6296, two other SNPs in HTR1B (i.e., rs130058 and rs6298) were also investigated in suicide completers. Then meta-analysis was performed, and we found that the rs6298 rather than rs130058 was significantly associated with an increased risk of suicidal behavior in a heterozygous comparison. Previous work has revealed that rs6296 and rs6298 displayed linkage disequilibrium (19), and thus it is difficult to understand how these SNPs might have different clinical consequences. We have to admit that the results may occur by chance due to limited studies included in this meta-analysis. Therefore, the relationship of rs6296, rs6298, and rs130058 with suicidal behavior will be an important issue that needs to be addressed in further studies.

Heterogeneity among studies was observed in the heterozygous comparison of rs6296 with the risk of suicidal behavior. Some common candidates such as ethnicity, genotyping methods and sample size (>200 and ≤200) were not demonstrated to affect heterogeneity, indicating that uncontrolled confounding factors and inherent selection bias may explain the heterogeneity. Publication bias observed in a few comparisons may be attributed to small sample size since the bias disappeared when excluding the studies with sample size <200. The results remained unaltered after omission of these studies, suggesting that the true association was not overestimated by selective publication of positive results.

Notably, most of the published studies focused on the effect of rs6296 on the risk of MDD and suicidal behavior. Only two studies investigated whether rs6296 influenced the outcome of anti-depressant treatment and whether rs6298 influenced the risk of suicidal ideation. Moreover, very limited studies included in our meta-analysis reported detailed information, such as matching criteria between cases and controls and quality control for genotyping assays. Given these limitations in this meta-analysis, genetic association studies are be of

![FIGURE 3](image-url) Egger’s funnel plot for publication bias test of HTR1B rs6296 polymorphism with MDD (A–D) and suicidal behavior (E–H). (A,E) GC vs. GG; (B,F) CC vs. GG; (C,G) GC/CC vs. GG; (D,H) CC vs. GG/GC.
great importance using well-designed multi-center cohorts with large samples.

In summary, this meta-analysis identified that rs6296 in HTR1B was significantly associated with the risk of MDD and rs6298 in HTR1B was significantly associated with the risk of suicidal behavior. Further studies investigating the relative contribution of SNPs in HTR1B and the mechanisms by which they affect the susceptibility of developing MDD, ADR and suicidal behavior are warranted.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**AUTHOR CONTRIBUTIONS**

YL and SH designed the study and wrote the manuscript. PY and MY managed the literature searches and analyses. PL, DC, DG, LP, and JL undertook the statistical analysis. All authors contributed to and have approved the final manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (no. 81901379), Major Projects of the Education Department of Sichuan (no. 18ZA0146), Development and Regeneration Key Lab of Sichuan Province (no. SYS17-007), Innovation Team Project of Chengdu Medical College (no. CYTD17-05), and post project of the National Natural Science Foundation of China (219L008).

**REFERENCES**

1. Collaborators. GDaIIaP. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. (2016) 388:1545–602. doi: 10.1016/S0140-6736(16)31678-6

2. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. (2013) 14:334–85. doi: 10.3109/15622975.2013.804195

3. Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder-update 2015. *World J Biol Psychiatry*. (2015) 16:76–95. doi: 10.3109/15622975.2014.1001786

4. Ferrari AJ, Charlson FF, Norman RE, Patton SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. *PLoS Med*. (2013) 10:e1001547. doi: 10.1371/journal.pmed.1001547

5. Kessler RC, Berglund P, Demler O, Jin R, Koretz DL, Williams JB, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. (2003) 289:3095–3105. doi: 10.1001/jama.289.21.3095

6. Monroe SM, Slavich GM, Torres LD, Gotlib IH. Major life events and the mechanisms by which they affect the risk of major depressive disorder. *Arch Gen Psychiatry*. (2007) 64:768–79. doi: 10.1001/archpsyc.60.8.789

7. Monroe SM, Slavich GM, Torres LD, Gotlib IH. Major life events and major chronic difficulties are differentially associated with history of major depressive episodes. *J Abnorm Psychol*. (2007) 116:116–24. doi: 10.1037/0021-843X.116.1.116

8. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depressive disorder: review and meta-analysis. *Arch Gen Psychiatry*. (2000) 57:1552–62. doi: 10.1176/appi.ajp.157.10.1552

9. Bellmaker RH, Agam G. Major depressive disorder. *N Engl J Med*. (2008) 358:53–68. doi: 10.1056/NEJMra070396

10. aan het Rot M, Mathew SJ, Charnley DS. Neurobiological mechanisms in major depressive disorder. *CMAJ*. (2009) 180:635–13. doi: 10.1503/cmaj.080697

11. Taciak PP, Lysenko N, Mazurek AP. Drugs which influence serotonin transporter and serotonin receptors: Pharmacological and clinical properties in the treatment of depression. *Pharmacol Rep*. (2018) 70:37–46. doi: 10.1016/j.pharep.2017.07.011

12. Xiang C, Liu S, Fan Y, Wang X, Jia Y, Li L, et al. Single nucleotide polymorphisms, variable number tandem repeats and allele influence on serotonergic enzyme modulators for aggressive and suicidal behaviors: a review. *Pharmacol Biochem Behav*. (2019) 180:74–82. doi: 10.1016/j.pbb.2019.03.008

13. Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylór K, Bailey AM, et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. *Nat Neurosci*. (2013) 16:464–72. doi: 10.1038/nmn.3355

14. Zhang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R. Altered emotional states in knockout mice lacking 5-HTA1 or 5-HT1B receptors. *Neuropsychopharmacology*. (1999) 21:525–605. doi: 10.1038/sj.npp.1393571

15. Sanders AR, Cao Q, Taylor J, Levin TE, Badner JA, Cravchik A, et al. Genetic diversity of the human serotonin receptor 1B (HTR1B) gene. *Genomics*. (2001) 72:1–14. doi: 10.1006/geno.2000.6411

16. Fehr C, Grinshchuk N, Szegedi A, Anghelescu I, Klaew C, Singer P, et al. The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy. *Psychiatry Res*. (2000) 97:1–10. doi: 10.1016/S0165-1781(00)00215-8

17. Hong CJ, Pan GM, Tsai SJ. Association study of onset age, attempted suicide, aggressive behavior, and schizophrenia with a serotonin 1B receptor (A-161T) genetic polymorphism. *Neuropsychobiology*. (2004) 49:1–4. doi: 10.1159/000075330

18. Huang YW, Ouqouden MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. *Neuropsychopharmacology*. (2003) 28:163–9. doi: 10.1038/sj.npp.1300000

19. Kao WT, Yang MC, Lung FW. Association between HTR1B alleles and suicidal ideation in individuals with major depressive disorder. *Neurosci Lett*. (2017) 638:204–10. doi: 10.1016/j.neulet.2016.12.043

20. Murphy TM, Ryan M, Foster T, Kelly C, McClelland R, O’Grady J, et al. Risk and protective genetic variants in suicidal behaviour: association with SLCA1A, SLCA1A, 5-HTTR1B 861C polymorphisms. *Behav Brain Funct*. (2011) 7:22. doi: 10.1186/1744-9081-7-22

21. New AS, Gelernter J, Goodman M, Mitropoulou V, Koenigsberg H, Silverman D, et al. Genetic association analysis of serotonin and signal transduction pathways in suicide attempts from an Italian sample of psychiatric patients. *Neurosci Lett*. (2017) 656:94–102. doi: 10.1016/j.neulet.2017.07.020
25. Pooley EC, Houston K, Hawton K, Harrison PJ. Deliberate self-harm is associated with allelic variation in the tryptophan hydroxylase gene (TPH A779C), but not with polymorphisms in five other serotonergic genes. *Psychol Med.* (2003) 33:775–83. doi: 10.1017/S0033291703007463

26. Rujescu D, Giegling I, Sato T, Möller HJ. Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior. *Am J Med Genet B Neuropsychiatr Genet.* (2003) 116B:69–71. doi: 10.1002/ajmg.b.10732

27. Wang S, Zhang K, Xu Y, Sun N, Shen Y, Xu Q. An association study of the serotonin transporter and receptor genes with the suicidal ideation of major depression in a Chinese Han population. *Psychiatry Res.* (2009) 170:204–7. doi: 10.1016/j.psychres.2008.12.006

28. Sun HF, Chang YT, Fann CS, Chang CJ, Chen YH, Hsu YP, et al. Association study of novel human serotonin 5-HT(1B) polymorphisms with alcohol dependence in Taiwanese Han. *Biol Psychiatry.* (2002) 51:896–901. doi: 10.1016/S0006-3223(01)01386-X

29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* (2002) 21:1539–58. doi: 10.1002/sim.1186

30. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst.* (1959) 22:719–48.

31. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2

32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* (1997) 315:629–34. doi: 10.1136/bmj.315.709.629

33. Shaikh SA, Strauss J, King N, Bulgin NL, Vetró A, Kiss E, et al. Association study of serotonin system genes in childhood-onset mood disorder. *Psychiatr Genet.* (2008) 18:47–52. doi: 10.1097/YPG.0b013e3282f0ba8b

34. Silva H, Iturra P, Solari A, Villarroel I, Jerez S, Jiménez M, et al. Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder. *Psychiatr Clin.* (2010) 20:25–30. doi: 10.1016/j.pct.2010.03.001

35. Slopien R, Slopien A, Rózycka A, Warenik-Szymankiewicz A, Lianeri M, Jagodziński PP. The c.1460C>T polymorphism of MAO-A is associated with the risk of depression in postmenopausal women. *Sci World J.* (2012) 2012:194845. doi: 10.1155/2012/194845

36. Stefuļj J, Böttner A, Skavic J, Zill P, Balija M, Eisenmenger W, et al. Serotonin 1B (5HT-1B) receptor polymorphism (G861C) in suicide victims: association studies in German and Slavic population. *Am J Med Genet Part B Neuropsychiatr Genet.* (2004) 127B:48–50. doi: 10.1002/ajmg.b.20174

37. Tsai SJ, Hong CJ, Yu YW, Chen TJ, Wang YC, Lin WK. Association study of serotonin 1B receptor (A-161T) genetic polymorphism and suicidal behaviors and response to fluoxetine in major depressive disorder. *Neuropsychobiology.* (2004) 50:235–8. doi: 10.1159/000079977

38. Videtic A, Pungercic G, Pajner IZ, Zupanc T, Balazic J, Tomori M, et al. Association study of seven polymorphisms in four serotonin receptor genes on suicide victims. *Am J Med Genet Part B Neuropsychiatr Genet.* (2006) 141B:669–72. doi: 10.1002/ajmg.b.30390

39. Wang P, Lv Q, Mao Y, Zhang C, Bao C, Sun H, et al. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients. *J Affect Disord.* (2018) 228:222–8. doi: 10.1016/j.jad.2017.12.010

40. Wilkie MJ, Smith G, Day RK, Matthews K, Smith D, Blackwood D, et al. Polymorphisms in the SLCN6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. *Pharmacogenomics J.* (2009) 9:61–70. doi: 10.1038/sj.tpj.6500491

41. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, et al. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. *J Psychopharmacol.* (2012) 26:349–59. doi: 10.1177/0269881111414152

42. Zouk H, McGregor A, Lebel V, Benkelfat C, Rouleau G, Turecki G. The effect of genetic variation of the serotonin 1B receptor gene on impulsive aggressive behavior and suicide. *Am J Med Genet B Neuropsychiatr Genet.* (2007) 144B:996–1002. doi: 10.1002/ajmg.b.30521

43. Engel G, Gotthert M, Hoyer D, Schlicker E, Hillenbrand K. Brand of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. *Naunyn-Schmiedeberg's Arch Pharmacol.* (1986) 332:1–7. doi: 10.1007/BF00633189

44. Gingrich JA, Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. *Psychopharmacology.* (2001) 155:1–10. doi: 10.1007/s002130000573

45. Crabbe JC, Phillips TJ, Feller DJ, Hen R, Wenger CD, Lessov CN, et al. Elevated alcohol consumption in null mutant mice lacking 5-HT1B serotonin receptors. *Nat Genet.* (1996) 14:98–101. doi: 10.1038/ng0996-98

46. Rocha BA, Scarce-Lievie K, Lucas JJ, Hirotori N, Castanon N, Crabbe JC, et al. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. *Nature.* (1998) 393:175–8. doi: 10.1038/30259

47. Ruf BM, Bhawagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. *Curr Drug Targets.* (2009) 10:1118–38. doi: 10.2174/1389450909789735192

48. Tiger M, Varnas K, Okubo Y, Lundberg J. The 5-HT1B receptor - a potential target for antidepressant treatment. *Psychopharmacology.* (2018) 235:1317–34. doi: 10.1007/s00213-018-4872-1

49. Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V, et al. Genome-wide association study of comorbidity depressive syndrome and alcohol dependence. *Psychiatr Genet.* (2012) 22:31–41. doi: 10.1097/YPG.0b013e32834acdd07

50. Garriock HA, Kraft JB, Shyn SJ, Peters EJ, Yokoyama JS, Jenkins GD, et al. A genomewide association study of citalopram response in major depressive disorder. *Biol Psychiatry.* (2010) 67:133–8. doi: 10.1016/j.biopsych.2009.08.029

51. Richardson AS, Bergen HA, Martin G, Roeger L, Allison S. Perceived academic performance as an indicator of risk of attempted suicide in young adolescents. *Arch Suicide Res.* (2005) 9:163–76. doi: 10.1080/13811110590904016

52. Kia-Keating BM, Glatt SJ, Tsuang MT. Meta-analyses suggest association between COMT, but not HTR1B, alleles, and suicidal behavior. *Am J Med Genet B Neuropsychiatr Genet.* (2007) 144B:1048–53. doi: 10.1002/ajmg.b.30551

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yang, Yang, Li, Cao, Gong, Lv, Pu, Huang and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.